NASDAQ · TELO

Telomir Pharmaceuticals, Inc. Common Stock

Healthcare · Biotechnology

$1.16

Up+$0.00 (+0.00%)

Updated Sep 6, 2026, 9:42 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap: 50.71M
P/E ratio: -4.07
Dividend yield: 0.00%
52-week range: $0.89 – $1.50
Volume: 33.92K
Avg. volume: 1.83M

Price performance

TELO price history

1M range · 20 trading sessions · Daily adjusted prices

Last close: $1.16
Period change: -0.85%
Period low: $1.05
Period high: $1.19

Daily close

View OHLC price history

TELO OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Sep 4, 2026	$1.17	$1.19	$1.16	$1.16	33.92K
Sep 3, 2026	$1.12	$1.17	$1.11	$1.16	64.23K
Sep 2, 2026	$1.11	$1.13	$1.0885	$1.12	31.38K
Sep 1, 2026	$1.13	$1.13	$1.085	$1.10	19.57K
Aug 31, 2026	$1.11	$1.14	$1.08	$1.12	45.43K
Aug 28, 2026	$1.20	$1.20	$1.14	$1.14	38.24K
Aug 27, 2026	$1.16	$1.20	$1.145	$1.19	131.18K
Aug 26, 2026	$1.17	$1.20	$1.1412	$1.17	69.09K
Aug 25, 2026	$1.18	$1.196	$1.156	$1.18	40.83K
Aug 24, 2026	$1.13	$1.20	$1.13	$1.17	56.36K
Aug 21, 2026	$1.13	$1.16	$1.1099	$1.13	43.39K
Aug 20, 2026	$1.18	$1.18	$1.11	$1.13	35.3K
Aug 19, 2026	$1.10	$1.20	$1.10	$1.17	100.76K
Aug 18, 2026	$1.05	$1.085	$1.0312	$1.08	28.5K
Aug 17, 2026	$1.10	$1.11	$1.05	$1.06	48.46K
Aug 14, 2026	$1.05	$1.135	$1.05	$1.09	58.44K
Aug 13, 2026	$1.09	$1.10	$1.04	$1.05	87.06K
Aug 12, 2026	$1.14	$1.14	$1.075	$1.11	52.59K
Aug 11, 2026	$1.17	$1.1811	$1.13	$1.13	27.58K
Aug 10, 2026	$1.16	$1.19	$1.15	$1.17	36.83K

Latest TELO news

The latest Smart Investors Daily articles mentioning TELO.

sec filingJul 29, 2026

Telomir Pharmaceuticals, Inc. (TELO) Files Proxy Statement Ahead of Shareholder Meeting

Latest TELO news

The latest Smart Investors Daily articles mentioning TELO.

Stock researchResearch & News · SEC Filings

Company

Overview Forecast Earnings Dividend Financials

Market Activity

Options Insider Trades Short Interest Institutional Ownership Sentiment

Research & News

Analysis Competitors News SEC Filings SID Coverage

TELO research

SEC Filings

Recent regulatory filings and source documents.

TELO SEC filings
Filed	Form	Description	Accepted	Document
Aug 13, 2026	10-Q	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	—	Open source
Aug 10, 2026	8-K	Form 8-K - Current report - Item 7.01 Item 9.01	—	Open source
Jul 28, 2026	DEF 14A	Form DEF 14A - Other definitive proxy statements	—	Open source
Jul 27, 2026	4	Form 4 - Statement of changes in beneficial ownership of securities	—	Open source
Jul 27, 2026	4	Form 4 - Statement of changes in beneficial ownership of securities	—	Open source
Jul 27, 2026	4	Form 4 - Statement of changes in beneficial ownership of securities	—	Open source
Apr 30, 2026	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Apr 24, 2026	8-K	Form 8-K - Current report - Item 1.01 Item 2.01 Item 3.02 Item 9.01	—	Open source
Mar 31, 2026	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Mar 31, 2026	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Mar 27, 2026	8-K	Form 8-K - Current report - Item 5.02 Item 5.03 Item 5.07 Item 9.01	—	Open source
Mar 17, 2026	10-K	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	—	Open source
Jan 5, 2026	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Nov 24, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Nov 20, 2025	8-K	Form 8-K - Current report - Item 5.02 Item 9.01	—	Open source
Nov 20, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Nov 12, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Nov 10, 2025	10-Q	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	—	Open source
Oct 22, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Oct 20, 2025	8-K	Form 8-K - Current report - Item 1.01 Item 9.01	—	Open source
Oct 14, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Oct 8, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Oct 6, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Sep 18, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Sep 9, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Sep 4, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Aug 27, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Aug 14, 2025	10-Q	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	—	Open source
Aug 7, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jul 23, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jul 22, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jul 17, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jun 18, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jun 11, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jun 5, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Jun 2, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
May 30, 2025	4	Form 4 - Statement of changes in beneficial ownership of securities	—	Open source
May 29, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
May 21, 2025	8-K	Form 8-K - Current report - Item 1.01 Item 3.02 Item 5.02 Item 9.01	—	Open source
May 21, 2025	8-K	Form 8-K - Current report - Item 3.02 Item 8.01	—	Open source
May 15, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
May 14, 2025	10-Q	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	—	Open source
May 7, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Mar 19, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Feb 25, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Feb 20, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Feb 18, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source
Feb 14, 2025	S-3	Form S-3 - Registration statement under Securities Act of 1933	—	Open source
Feb 4, 2025	10-K	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	—	Open source
Jan 28, 2025	8-K	Form 8-K - Current report - Item 8.01	—	Open source

Filed

Form

Description

Accepted

Document

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

—

Open source

Aug 10, 2026

8-K

Form 8-K - Current report - Item 7.01 Item 9.01

—

Open source

Jul 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

—

Open source

Jul 27, 2026

Form 4 - Statement of changes in beneficial ownership of securities

—

Open source

Jul 27, 2026

Form 4 - Statement of changes in beneficial ownership of securities

—

Open source

Jul 27, 2026

Form 4 - Statement of changes in beneficial ownership of securities

—

Open source

Apr 30, 2026

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Apr 24, 2026

8-K

Form 8-K - Current report - Item 1.01 Item 2.01 Item 3.02 Item 9.01

—

Open source

Mar 31, 2026

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Mar 31, 2026

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Mar 27, 2026

8-K

Form 8-K - Current report - Item 5.02 Item 5.03 Item 5.07 Item 9.01

—

Open source

Mar 17, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

—

Open source

Jan 5, 2026

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Nov 24, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Nov 20, 2025

8-K

Form 8-K - Current report - Item 5.02 Item 9.01

—

Open source

Nov 20, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Nov 12, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

—

Open source

Oct 22, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Oct 20, 2025

8-K

Form 8-K - Current report - Item 1.01 Item 9.01

—

Open source

Oct 14, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Oct 8, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Oct 6, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Sep 18, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Sep 9, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Sep 4, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Aug 27, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

—

Open source

Aug 7, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jul 23, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jul 22, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jul 17, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jun 18, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jun 11, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jun 5, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Jun 2, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

May 30, 2025

Form 4 - Statement of changes in beneficial ownership of securities

—

Open source

May 29, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

May 21, 2025

8-K

Form 8-K - Current report - Item 1.01 Item 3.02 Item 5.02 Item 9.01

—

Open source

May 21, 2025

8-K

Form 8-K - Current report - Item 3.02 Item 8.01

—

Open source

May 15, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

May 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

—

Open source

May 7, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Mar 19, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Feb 25, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Feb 20, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Feb 18, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Feb 14, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

—

Open source

Feb 4, 2025

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

—

Open source

Jan 28, 2025

8-K

Form 8-K - Current report - Item 8.01

—

Open source

Telomir Pharmaceuticals, Inc. (TELO) Files Proxy Statement Ahead of Shareholder Meeting

Featured By

Telomir Pharmaceuticals, Inc. (TELO) Files Proxy Statement Ahead of Shareholder Meeting